Human fibroblasts transduced with CD80 or CD86 efficiently trans- costimulate CD4+ and CD8+ T lymphocytes in HLA-restricted reactions: Implications for immune augmentation cancer therapy and autoimmunity

Journal of Immunology

Volumn 163, Issue 6, 1999, Pages 3239-3249

  Smythe, Jason A ^a   Fink, Peter D ^a   Logan, Grant J ^a   Lees, Jacqueline ^a   Rowe, Peter B ^a   Alexander, Ian E ^b  

^a CHILDREN'S MEDICAL RESEARCH INSTITUTE   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ARTICLE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; FIBROBLAST; HELPER CELL; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

3T3 CELLS; ANIMALS; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; AUTOIMMUNE DISEASES; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; FIBROBLASTS; GAMMA RAYS; GENE EXPRESSION REGULATION; GENETIC VECTORS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA ANTIGENS; HUMANS; KINETICS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; RETROVIRIDAE; SARCOMA, ALVEOLAR SOFT PART; TRANSGENES; TUMOR CELLS, CULTURED;

EID: 0033568302     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Freeman, G. J., A. S. Freeman, J. M. Segil, G. Lee, J. F. Whitman, and L. M. Nadler. 1989. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J. Immunol. 143:1714.
2. Gimmi, C. D., G. J. Freeman, J. G. Gribben, K. Sugita, A. S. Freeman, C. Morimoto, and L. M. Nadler. 1991. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc. Natl. Acad. Sci. USA 88:6575.
3. Nabavi, N., G. J. Freeman, A. Gault, D. Godfrey, L. M. Nadler, and L. H. Glimcher. 1992. Signalling through the MHC class-II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature 360:266.
4. + T cells by B7-transfected melanoma cells. Science 259:368.
5. Hathcock, K. S., G. Laszlo, H. B. Dickler, J. Bradshaw, P. Linsley, and R. J. Hodes. 1993. Identification of an alternative CTLA-4 ligand costimulatory for T-cell activation. Science 262:905.
6. Freeman, G. J., F. Borriello, R. J. Hodes, H. Reiser, K. S. Hathcock, G. Laszlo, A. J. McKnight, J. Kim, L. Du, D. B. Lombard, G. S. Gray, L. M. Nadler, and A. H. Sharpe. 1993. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 262:907.
7. Freeman, G. J., J. G. Gribben, V. A. Boussiotis, J. W. Ng, V. A. Restivo, L. A. Lombard, G. S. Gray, and L. M. Nadler. 1993. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262:909.
8. Azuma, M., D. Ito, H. Yagita, K. Okumura, J. H. Phillips, L. L. Lannier, and C. Somoza. 1993. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366:76.
9. Engel, P., J. G. Gribben, G. J. Freeman, L.-J. Zhou, Y. Nozawa, M. Abe, L. M. Nadler, H. Wakasa, and T. F. Tedder. 1994. The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen. Blood 84:1402.
10. Bretscher, P., and M. Cohn. 1970. A theory of self-nonself discrimination. Science 169:1042.
11. Freeman, G. J ., G. S. Gray, C. D. Gimmi, D. B. Lombard, L.-J. Zhou, M. White, J. D. Fingeroth, J. G. Gribben, and L. M. Nadler. 1991. Structure, expression, and T-cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J. Exp. Med. 174:625.
12. Hathcock, K. S., G. Laszlo, C. Pucillo, P. Linsley, and R. J. Hodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180:631.
13. Chen, L., S. Ashe, W. A. Brady, I. Hellstrom, K. E. Hellstrom, J. A. Ledbetter, P. McGowan, and P. S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 71:1093.
14. Baskar, S., S. Ostrand-Rosenberg, N. Nabavi, L. M. Nadler, G. J. Freeman, and L. H. Glimcher. 1993. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class-II molecules. Proc. Natl. Acad. Sci. USA 90:5687.
15. Plautz, G., Z.-Y. Yang, B.-Y. Wu, X. Gao, L. Huang, and G. Nabel. 1993. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc. Natl. Acad. Sci. USA 90:4645.
16. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J. Immunol. 153: 421.
17. Hodge, J. W., S. Abrams, J. Schlom, and J. Kantor. 1994. Induction of antitumor immunity by recombinant vaccinia virus expressing B7-1 or B7-2 costimulatory molecules. Cancer Res. 54:5552.
18. Chen, L., P. McGowan, S. Ashe, J. Johnson, Y. Li, I. Hellstrom, and K. Hellstrom. 1994. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179:523.
19. Dohring, C., L. Angman, G. Spagnoli, and A. Lanzavecchia. 1994. T-helper and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int. J. Cancer 57:754.
20. Katsanis, E., Z. Xu, M. Bausero, B. Dancisak, K. Gorden, G. Davis, G. S. Gray, P. J. Orchard, and B. R. Blazar. 1995. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules. Cancer Gen. Ther. 2:39.
21. Harlan, D. M., H. Hengartner, M. L. Huang, Y.-H. Kang, R. Abe, R. W. Moreadith, H. Pircher, G. S. Gray, P. S. Ohashi, G. J. Freeman, L. M. Nadler, C. H. June, and P. Aichele. 1994. Mice expressing both B7-1 and viral glycoprotein on pancreatic β cells along with glycoprotein-specific transgenic T-cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness. Proc. Natl. Acad. Sci. USA 91:3137.
22. Williams, I. R., R. J. Ort, and T. S. Kupper. 1994. Keratinocyte expression of B7-1 in transgenic mice amplifies the primary immune response to cutaneous antigens. Proc. Natl. Acad. Sci. USA 91:12780.
23. Guerder, S., D. E. Picarella, P. S. Linsley, and R. A. Flavell 1994. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor α leads to autoimmunity in mice. Proc. Natl. Acad. Sci. USA 91:5138.
24. Bellone, M., G. Iezzi, A. A. Manfredi, M. P. Protti, P. Dellabona, G. Casorati, and C. Rugarli. 1994. In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. Eur. J. Immunol. 24:2691.
25. Martin-Fontecha, A., F. Cavallo, M. Ballone, S. Heltai, G. Iezzi, P. Tornaghi, N. Nabavi, G. Forni, P. Dellabonna, and G. Casorati. 1996. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. Eur. J. Immunol 26:1851.
26. Cardoso, A. A., M. J. Seamon, H. M. Alfonso, P. Ghia, V. A. Boussiotis, G. J. Freeman, J. G. Gribben, S. E. Sallan, and L. M. Nadler. 1997. Ex vivo generation of human anti-pre-B leukemia-specific autologous cytotoxic T cells. Blood 90:549.
27. Jenkins, M. K., J. D. Ashwell, and R. H. Schwartz. 1988. Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells. J. Immunol. 140:3324.
28. Liu, Y., and C. A. Janeway. 1992. Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc. Natl. Acad. Sci. USA 89:3845.
29. Tan, P., C. Anasetti, J. A. Hansen, J. Melrose, M. Brunvand, J. Bradshaw, J. A. Ledbetter, and P. S. Linsey. 1993. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J. Exp. Med. 177:165.
30. + naive T cells can be efficiently activated by remote co-stimulation with B7. Int. Immunol. 5:1483.
31. + T cells by delivery of the B7 costimulatory signal on bystander antigen-presenting cells (trans-costimulation). Eur. J. Immunol. 24:859.
32. Marelli-Berg, F. M., R. E. G. Hargreaves, P. Carmichael, A. Dorling, G. Lombardi, and R. I. Lechler. 1996. Major histocompatibility complex class II-expressing endothelial cells induce allospecific nonresponsiveness in naive T cells. J. Exp. Med. 183:1603.
33. Miller, A. D., and G. J. Rosman. 1989. Improved retroviral vectors for gene transfer and expression. BioTechniques. 7:980.
34. Smyth, C., G. Logan, R. Weinberger, P. B. Rowe, I. E. Alexander, and J. A. Smythe. 1998. Identification of a dynamic intracellular reservoir of CD86 protein in peripheral blood monocytes that is not associated with the Golgi complex. J. Immunol. 160:5390.
35. Miller, A. D., D. G. Miller, J. V. Garcia, and C. M. Lynch. 1993. The use of retroviral vectors for gene transfer and expression. Methods Enzymol. 217:581.
36. Pechhold, K., N. B. Patterson, N. Craighead, K. P. Lee, C. H. June, and D. M. Harlan. 1997. Inflammatory cytokines IFN-γ plus TNF-α induce regulated expression of CD80 (B7-1) but not CD86 (B7-2) on murine fibroblasts. J. Immunol. 158:4921.
37. Dalgleish, A. G., and M. Browning, eds. 1996. Tumor Immunology: Immunotherapy and Cancer Vaccines. Cambridge University Press, Cambridge, U.K.
38. Diao, J., J. A. Smythe, C. Smyth, P. B. Rowe, and I. E. Alexander. 1999. Human PBMC-derived dendritic cells transduced with an adenovirus vector induce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro. Gene Ther. 6:845.